{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:38:10Z","timestamp":1765280290920,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The present study provides a snapshot of Italian patients with peritoneal metastasis from gastric cancer treated by surgery in Italian centers belonging to the Italian Research Group on Gastric Cancer. Prognostic factors affecting survival in such cohort of patients were evaluated with the final aim to identify patients who may benefit from radical intent surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>It is a multicentric retrospective study based on a prospectively collected database including demographics, clinical, surgical, pathological, and follow-up data of patients with gastric cancer and synchronous macroscopic peritoneal metastases. Patients were surgically treated from January 2005 to January 2017. We focused on patients with macroscopic peritoneal carcinomatosis (PC) treated with upfront surgery in order to provide homogeneous evidences.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our results show that patients with peritoneal carcinomatosis cannot be considered all lost. Strictly selected cases (R0\/R1 and P1 patients) could benefit from an aggressive surgical approach performing an extended lymphadenectomy and HIPEC treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The main result of the study is that GC patients with limited peritoneal involvement can have a survival benefit from a surgery with \u201cradical oncological intent\u201d, that means extended lymphadenectomy and R0 resection. The retrospective nature of this study is an important bias, and for this reason, we have started a prospective multicentric study including Italian stage IV patients that hopefully will give us more answers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-021-02442-9","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T12:03:17Z","timestamp":1637755397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Looking for a strategy in treating peritoneal gastric cancer carcinomatosis: an Italian multicenter Gastric Cancer Research group\u2019s analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Luigina","family":"Graziosi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-503X","authenticated-orcid":false,"given":"Elisabetta","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Bencivenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"D\u2019Ignazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Solaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Ministrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Caprioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Marrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Mura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Degiuli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Morgagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido Alberto Massimo","family":"Tiberio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"De Manzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annibale","family":"Donini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"2442_CR1","volume-title":"Global cancer observatory: cancer today","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, et al. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2018. Available from: https:\/\/gco.iarc.fr\/today. Accessed 28 Dec 2018"},{"key":"2442_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"3","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;3:215\u201321.","journal-title":"Lancet Oncol"},{"key":"2442_CR3","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1158\/1078-0432.CCR-05-2425","volume":"12","author":"K Yoshida","year":"2006","unstructured":"Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006;12:3402\u20137.","journal-title":"Clin Cancer Res"},{"key":"2442_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00432-013-1563-5","volume":"140","author":"W Koizumi","year":"2014","unstructured":"Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140:319\u201328.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2442_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1477-7819-8-40","volume":"8","author":"K Tanabe","year":"2010","unstructured":"Tanabe K, Suzuki T, Tokumoto N, Yamamoto H, Yoshida K, Ohdan H. Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis. World J Surg Oncol. 2010;8:40.","journal-title":"World J Surg Oncol"},{"key":"2442_CR6","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1016\/S1470-2045(13)70436-4","volume":"14","author":"L Shen","year":"2013","unstructured":"Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535\u201347.","journal-title":"Lancet Oncol"},{"key":"2442_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10120-005-0321-z","volume":"8","author":"F Lordick","year":"2005","unstructured":"Lordick F, Siewert J. Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer. 2005;8:78\u201385.","journal-title":"Gastric Cancer"},{"key":"2442_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","volume":"19","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329\u201338. https:\/\/doi.org\/10.1007\/s10120-015-0575-z.","journal-title":"Gastric Cancer"},{"key":"2442_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival, and risk factors. Int J Cancer. 2014;134:622\u20138.","journal-title":"Int J Cancer"},{"key":"2442_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12885-015-1081-8","volume":"15","author":"F Seyfried","year":"2015","unstructured":"Seyfried F, von Rahden BH, Miras AD, et al. Incidence, time course, and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin: a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer. 2015;15:73.","journal-title":"BMC Cancer"},{"key":"2442_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/01.sla.0000143245.28656.15","volume":"240","author":"M D\u2019Angelica","year":"2004","unstructured":"D\u2019Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808\u201316.","journal-title":"Ann Surg"},{"key":"2442_CR12","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/bjs.4164","volume":"90","author":"F Roviello","year":"2003","unstructured":"Roviello F, Marrelli D, de Manzoni G, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113.","journal-title":"Br J Surg"},{"key":"2442_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/jso.21519","volume":"101","author":"XJ Yang","year":"2010","unstructured":"Yang XJ, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and\/or peritoneal carcinomatosis: results from a Chinese center. J Surg Oncol. 2010;101:457\u201364.","journal-title":"J Surg Oncol"},{"issue":"9","key":"2442_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/bjs.7528","volume":"98","author":"D Marrelli","year":"2011","unstructured":"Marrelli D, Pedrazzani C, Morgagni P, de Manzoni G, Pacelli F, Coniglio A, et al. Changing clinical and pathological features of gastric cancer over time. Br J Surg. 2011;98(9):1273\u201383.","journal-title":"Br J Surg"},{"issue":"7","key":"2442_CR15","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1158\/1055-9965.EPI-09-0250","volume":"18","author":"H Wu","year":"2009","unstructured":"Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009;18(7):1945\u201352.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"2442_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/ijc.20047","volume":"109","author":"A Verdecchia","year":"2004","unstructured":"Verdecchia A, Corazziari I, Gatta G, Lisi D, Faivre J, Forman D, et al. Explaining gastric cancer survival differences among European countries. Int J Cancer. 2004;109(5):737\u201341.","journal-title":"Int J Cancer"},{"issue":"1","key":"2442_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00423-016-1536-7","volume":"402","author":"H Hosogi","year":"2017","unstructured":"Hosogi H, Shinohara H, Tsunoda S, Hisamori S, Sumida H, Hida K, et al. Staging laparoscopy for advanced gastric cancer: significance of preoperative clinicopathological factors. Langenbecks Arch Surg. 2017;402(1):33\u20139. https:\/\/doi.org\/10.1007\/s00423-016-1536-7 Epub 2016 Nov 29.","journal-title":"Langenbecks Arch Surg"},{"key":"2442_CR18","doi-asserted-by":"publisher","unstructured":"De Manzoni G, Marrelli D, Baiocchi GL, Morgagni P, Saragoni L, Degiuli M, et al. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment. Gastric Cancer. 2015. https:\/\/doi.org\/10.1007\/s10120-016-0615-3.","DOI":"10.1007\/s10120-016-0615-3"},{"key":"2442_CR19","doi-asserted-by":"publisher","unstructured":"Solaini L, Ministrini S, Bencivenga M, et al. Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study. Gastric Cancer. 2019. https:\/\/doi.org\/10.1007\/s10120-019-00968-2.","DOI":"10.1007\/s10120-019-00968-2"},{"issue":"8","key":"2442_CR20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.ejso.2016.03.030","volume":"42","author":"GA Tiberio","year":"2016","unstructured":"Tiberio GA, Ministrini S, Gardini A, Marrelli D, Marchet A, Cipollari C, et al. Factors influencing survival after hepatectomy for metastases from gastric cancer. Eur J Surg Oncol. 2016;42(8):1229\u201335. https:\/\/doi.org\/10.1016\/j.ejso.2016.03.030 Epub 2016 Apr 19.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"2442_CR21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/jjco\/hyn058","volume":"38","author":"K Fujitani","year":"2008","unstructured":"Fujitani K, Yang HK, Kurokawa Y, Park DJ, Tsujinaka T, Park BJ, et al. Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol. 2008;38(7):504\u20136.","journal-title":"Jpn J Clin Oncol"},{"key":"2442_CR22","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1093\/ejcts\/ezs574","volume":"43","author":"S Shiono","year":"2013","unstructured":"Shiono S, Sato T, Horio H, et al. Outcomes and prognostic factors of survival after pulmonary resection for metastatic gastric cancer. Eur J Cardiothorac Surg. 2013;43:e13\u20136.","journal-title":"Eur J Cardiothorac Surg"},{"key":"2442_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/oxfordjournals.annonc.a058778","volume":"5","author":"B Glimelius","year":"1994","unstructured":"Glimelius B, Hoffman K, Haglund U, Nyren O, Sj\u00f6d\u00e9n PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994;5:189\u201390.","journal-title":"Ann Oncol"},{"key":"2442_CR24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/bjc.1995.114","volume":"71","author":"S Pyrhonen","year":"1995","unstructured":"Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587\u201391.","journal-title":"Br J Cancer"},{"issue":"8","key":"2442_CR25","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.dld.2018.04.025","volume":"50","author":"A Zaanan","year":"2018","unstructured":"Zaanan A, Bouch\u00e9 O, Benhaim L, Buecher B, Chapelle N, Dubreuil O, et al. Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis. 2018;50(8):768\u201379. https:\/\/doi.org\/10.1016\/j.dld.2018.04.025 Epub 2018 Jun 6.","journal-title":"Dig Liver Dis"},{"key":"2442_CR26","doi-asserted-by":"publisher","unstructured":"Japanese Gastric Cancer Association Gastric Cancer. 1998. p. 1\u201310. https:\/\/doi.org\/10.1007\/PL00011681.","DOI":"10.1007\/PL00011681"},{"key":"2442_CR27","volume-title":"Manual for staging of cancer 1978","author":"American Joint Committee for Cancer Staging and End-Results Reporting","year":"1978","unstructured":"American Joint Committee for Cancer Staging and End-Results Reporting. Manual for staging of cancer 1978. Chicago: American Joint Committee; 1978."},{"issue":"2","key":"2442_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5230\/jgc.2020.20.e15","volume":"20","author":"DKA Chia","year":"2020","unstructured":"Chia DKA, So JBY. Recent advances in intra-peritoneal chemotherapy for gastric cancer. J Gastric Cancer. 2020;20(2):115\u201326. https:\/\/doi.org\/10.5230\/jgc.2020.20.e15 Epub 2020 Apr 10. PMID: 32595996; PMCID: PMC7311211.","journal-title":"J Gastric Cancer"},{"key":"2442_CR29","doi-asserted-by":"crossref","unstructured":"Cunningham D, Tebbutt NC, Davidenko I, et al. Phase III, randomized, double- blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G\/GEJ) cancer: RILOMET-1 study.\u00a0J Clin Oncol.\u00a02015;33:15_suppl, 4000-4000.","DOI":"10.1200\/jco.2015.33.15_suppl.4000"},{"key":"2442_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9","volume":"85","author":"S Fujimoto","year":"1999","unstructured":"Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1999;85:529\u201334.","journal-title":"Cancer"},{"key":"2442_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/BF00348209","volume":"18","author":"T Fujimura","year":"1994","unstructured":"Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg. 1994;18:150\u20135.","journal-title":"World J Surg"},{"key":"2442_CR32","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2442_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(15)00553-7 Epub 2016 Jan 26. PMID: 26822397.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2442_CR34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3109\/0284186X.2013.850740","volume":"53","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, Bernards N, Van Gestel Y. Chemotherapy as palliative treatment for peritoneal carcinomatosis of gastric origin. Acta Oncol. 2014;53(3):429\u201332. https:\/\/doi.org\/10.3109\/0284186X.2013.850740 Epub 2013 Dec 5.","journal-title":"Acta Oncol"},{"key":"2442_CR35","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/annonc\/mdl501","volume":"18","author":"J Lee","year":"2007","unstructured":"Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18:886\u20139.","journal-title":"Ann Oncol"},{"key":"2442_CR36","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/SLA.0b013e3181b0c80e","volume":"250","author":"M Kuramoto","year":"2009","unstructured":"Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraoperative peri- toneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 2009;250:242\u20136.","journal-title":"Ann Surg"},{"key":"2442_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jss.2019.07.044","volume":"245","author":"Y Gong","year":"2020","unstructured":"Gong Y, Wang P, Zhu Z, Zhang J, Huang J, Wang T, et al. Benefits of surgery after NIPS for GC patients with peritoneal metastasis: a meta-analysis. J Surg Res. 2020;245:234\u201343.","journal-title":"J Surg Res"},{"key":"2442_CR38","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1245\/s10434-007-9487-4","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Black D, Sugarbaker PH, et al. A systemic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for respectable gastric cancer. Ann Surg Oncol. 2007;14:2702\u201313.","journal-title":"Ann Surg Oncol"},{"key":"2442_CR39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ssu.10042","volume":"21","author":"PH Sugarbaker","year":"2003","unstructured":"Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003;21:233\u201348.","journal-title":"Semin Surg Oncol"},{"key":"2442_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","volume":"40","author":"F Coccolini","year":"2014","unstructured":"Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. EJSO. 2014;40:12\u201326.","journal-title":"EJSO"},{"issue":"19","key":"2442_CR41","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36(19):1922\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2442_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jso.23633","volume":"110","author":"U Rudloff","year":"2014","unstructured":"Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110(3):275\u201384. https:\/\/doi.org\/10.1002\/jso.23633 Epub 2014 Jul 5. PMID: 25042700; PMCID: PMC6301031.","journal-title":"J Surg Oncol"},{"issue":"1","key":"2442_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/cancers12010158","volume":"12","author":"S Ministrini","year":"2020","unstructured":"Ministrini S, Bencivenga M, Solaini L, Cipollari C, Sofia S, Marino E, et al. Stage IV gastric cancer: the surgical perspective of the Italian Research Group on Gastric Cancer. Cancers (Basel). 2020;12(1):158. https:\/\/doi.org\/10.3390\/cancers12010158 PMID: 31936512; PMCID: PMC7016536.","journal-title":"Cancers (Basel)"},{"key":"2442_CR44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"A Bass","year":"2014","unstructured":"Bass A, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139. https:\/\/doi.org\/10.1038\/nature13480.","journal-title":"Nature"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02442-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-021-02442-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02442-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T12:18:39Z","timestamp":1637756319000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-021-02442-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2442"],"URL":"https:\/\/doi.org\/10.1186\/s12957-021-02442-9","relation":{},"ISSN":["1477-7819"],"issn-type":[{"type":"electronic","value":"1477-7819"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"2 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human data were retrieved and used according to the guidelines of Helsinki\u2019s declaration.All patients signed a written consent according to our institution policy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed a written consent according to our institution policy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare that they have no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"334"}}